Welcome to another edition of Weekly Thoughts. This edition features a presentation update on the JAK inhibitor therapies and the announcement of a new startup/treatment for hair growth that is also claimed to restore hair pigment. Wowzas. Let’s take a look.
Aclaris Therapeutics Jeffries Presentation
Acalaris Therapeutics CEO Dr. Neal Walker made a presentation on June 8, 2016 at the Jeffries 2016 Healthcare Conference displaying the current state and path ahead for Aclaris. These conferences are designed to attract investor attention for the respective companies who present at them. Things look good moving forward for Aclaris and the news that was shared is that the company is setting its sights on initiating a clinical trial for alopecia areata in the first half 2017. That would presumably mean that a clinical trial for a topical JAK inhibitor for the indication of androgenic alopecia would follow, but there has been no mention of it so far. One interesting tidbit from the presentation is that Aclaris has recently acquired the rights to some “Next Generation” JAK inhibitors which are covalently bonded. At this point I do not know what advantages they provide, but it sounds good.
This page contains both a recording of the webcast presentation and a link to the PDF presentation, just click on “webcast” next to the microphone. The webcast will be taken down after 14 days I believe. When watching the webcast I had to manually change the slides to sync with the presentation. We look forward to hearing about new progress from Aclaris.
RiverTown Therapeutics and the What?
This is definitely one of the most interesting things I’ve read in a while. According to this presentation description (S/O Xaser94 great dig), RiverTown Therapeutics has a new compound named RT1640 in the works that grows hair in bald areas, also restores hair pigment, is made from three agents that have strong safety profiles, and has been tested in seven humans so far. lol. That’s a lot. Here is the full paragraph:
“RiverTown Therapeutics is a clinical stage startup with a novel, topically applied prescription product that promotes the recruitment of new hair follicles, and/or rejuvenates existing follicles that have become dormant in humans with androgenic alopecia. The lead compound, RT1640 is a combination of three agents that together have thousands of people/years exposure in humans with excellent safety profiles. When applied to areas of hair loss (scalp, eyebrows, beard) RT1640 promotes the reanimation of hair follicles through the recruitment and differentiation of follicular stem cells, including melanocyte stem cells. As a result of these events, new hair grows over the bald areas. In addition, if the subject had achromotrichia (gray or white hair from color-loss) before hair loss, it grows back as pigmented hair. RT1640 has been tested in scores of animals and on seven humans with androgenic alopecia, all of whom have responded with hair growth. There are several follow-on indications beyond androgenic alopecia, including wound healing and idiopathic pulmonary fibrosis. All of the technologies rely on the company’s proprietary technology of recruitment and differentiation of stem cells in situ.”
The company has been founded by Dr. David Weinstein who has an extensive biotech background including founding GliaMed Inc. and being CSO to Intekrin Therapeutics. I hope to have more on this development soon.
That Ultimate Guide to Hair Regeneration 2016 is due for a makeover and is going to be getting pretty crowded soon.